JP2021523125A5 - - Google Patents

Info

Publication number
JP2021523125A5
JP2021523125A5 JP2020561786A JP2020561786A JP2021523125A5 JP 2021523125 A5 JP2021523125 A5 JP 2021523125A5 JP 2020561786 A JP2020561786 A JP 2020561786A JP 2020561786 A JP2020561786 A JP 2020561786A JP 2021523125 A5 JP2021523125 A5 JP 2021523125A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
therapeutic pharmaceutical
receptor agonist
salt
Prior art date
Application number
JP2020561786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523125A (ja
JPWO2019213558A5 (https=
JP7458032B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030652 external-priority patent/WO2019213558A1/en
Publication of JP2021523125A publication Critical patent/JP2021523125A/ja
Publication of JPWO2019213558A5 publication Critical patent/JPWO2019213558A5/ja
Publication of JP2021523125A5 publication Critical patent/JP2021523125A5/ja
Application granted granted Critical
Publication of JP7458032B2 publication Critical patent/JP7458032B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020561786A 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 Active JP7458032B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666675P 2018-05-03 2018-05-03
US62/666,675 2018-05-03
IN201841019588 2018-05-25
IN201841019588 2018-05-25
PCT/US2019/030652 WO2019213558A1 (en) 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Publications (4)

Publication Number Publication Date
JP2021523125A JP2021523125A (ja) 2021-09-02
JPWO2019213558A5 JPWO2019213558A5 (https=) 2022-05-13
JP2021523125A5 true JP2021523125A5 (https=) 2022-05-13
JP7458032B2 JP7458032B2 (ja) 2024-03-29

Family

ID=68386694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020561786A Active JP7458032B2 (ja) 2018-05-03 2019-05-03 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化

Country Status (9)

Country Link
US (1) US20210169978A1 (https=)
EP (2) EP3813942B1 (https=)
JP (1) JP7458032B2 (https=)
CN (1) CN112469474A (https=)
AU (1) AU2019262612B2 (https=)
BR (1) BR112020022395A2 (https=)
ES (1) ES2978951T3 (https=)
PL (1) PL3813942T3 (https=)
WO (1) WO2019213558A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
JP2024517334A (ja) * 2021-05-11 2024-04-19 ファーマズ，インコーポレイテッド コロナウイルス疾患（ｃｏｖｉｄ－１９）における急性呼吸窮迫症候群（ａｒｄｓ）の治療のための医薬組成物及び方法
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss
IN202411028038A (https=) * 2024-04-04 2025-05-23

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597891A (ja) * 1991-04-24 1993-04-20 Banyu Pharmaceut Co Ltd 血管弛緩ペプチド類
CA2578709C (en) * 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
US9829494B2 (en) 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
AU2008237062A1 (en) 2007-04-10 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted deuterium enriched thiophenes for the treatment of hypertension
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
AU2010241564B2 (en) * 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
BR112015004643A2 (pt) 2012-08-31 2017-07-04 Univ Midwestern métodos e composições para ressucitação hipotensiva
AU2014287427B2 (en) 2013-07-08 2019-11-21 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist

Similar Documents

Publication Publication Date Title
JP2021523125A5 (https=)
Wilson Clinical pharmacokinetics of teicoplanin
JP2019517542A5 (https=)
BR112012030641B1 (pt) Usos e composições para terapia farmacêutica oral
HUP0104085A2 (hu) Vazopresszin antagonisták alkalmazása pulmonáris hipertenzió kezelésére szolgáló gyógyszerkészítmények előállítására
JP2021523125A (ja) 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化
ES3043583T3 (en) Dapagliflozin for use in methods of treating chronic kidney disease
US20260102472A1 (en) Semaglutide in medical therapy
JP2004538319A5 (https=)
Seaton et al. Possible potentiation of warfarin by fluconazole
Honda et al. Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia
Bridgeman et al. Potassium-lowering agents for the treatment of nonemergent hyperkalemia: pharmacology, dosing and comparative efficacy
US20090285909A1 (en) Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof
JPWO2019213558A5 (https=)
JP2021531297A5 (https=)
JP2002326936A5 (https=)
CN102091052B (zh) 双环醇双层渗透泵控释片剂及其制备方法
Munger New agents for managing hyponatremia in hospitalized patients
JP2002505678A (ja) 腫瘍組織を選択的に制御するための、相乗効果を有する組成物
JPS58140017A (ja) 心不全治療剤
US4798811A (en) Combination preparation
Schernthaner et al. Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
WO2017037737A1 (en) Parenteral formulations of levosimendan
WO2007129618A1 (ja) 好中球の活性化および遊走因子の抑制剤およびその利用
JP2008533109A (ja) 利尿を促進するための複合治療